The UK and US have hammered out a significant commercial pact that will ensure no duties on UK pharmaceutical shipments being sold in the US market.
The Terms of the Accord
In exchange for the tariff guarantee, the UK has committed to raise expenditure on drugs through the public health system. This pledge guarantees that import taxes on these vital products will remain at nothing for a period of 36 months.
This deal is in response to previous statements to hike import taxes on branded pharmaceutical products, with increases floated reaching double the cost.
"This deal between the UK strengthens the international landscape for new treatments and introduces long-overdue fairness to U.S.–U.K. medicine commerce," a statement noted.
Trade Significance
Pharmaceuticals represent one of the the United Kingdom's biggest export categories to the United States, which is clearly the primary market for leading British pharmaceutical firms.
Statistics indicate that in the year to the end of the third quarter, the UK exported medicines totaling £11.1bn to the US. This figure accounted for nearly one-fifth of all goods exports in that timeframe.
"This deal safeguards work, boosts capital expenditure and facilitates the UK to emerge as a international leader for medical research," a minister stated.
Key British Pledges
The deal includes several specific pledges from the UK:
- Price Threshold Increase: The UK will lift the price threshold at which it deems new medicines to be prohibitively costly by 25%.
- Increased NHS Spending: There is a goal to increase overall public funding on drugs from 0.3% of GDP to 0.6 percent over the following ten-year period.
- Rebate Cap: The percentage manufacturers must return to the NHS to prevent overspending will be limited at fifteen percent. In the past, repayments were more than twenty percent.
Industry Background
The pact comes amid a long-running dispute between the drug companies and the British authorities over medicine costs and regulatory access.
The disagreement were intensified by arguments that US customers were charged several times more for the equivalent treatments than patients in the Britain and the EU.
Recently, several large drug company projects in the UK have been paused or scrapped, while substantial expansions have been pledged toward projects in the United States.
The Science Minister acknowledged that the NHS needed to spend more on medicines, noting that its budget allocation on drugs had shrunk as a proportion of its total funding over the last ten years.
